# Imaging

> **NIH NIH P01** · UNIVERSITY OF LOUISIANA AT LAFAYETTE · 2020 · $230,704

## Abstract

Abstract – Core D (NHP Imaging)
The overall objective of Core D (Imaging Core) is to provide expertise and start-of-the-art technology for non-
invasive imaging of experimental non-human primates (rhesus macaques) to achieve the goals of this HIVRAD
Program. Core D is located in the Research Imaging Institute (RII) at the University of Texas Health Science
Center - San Antonio (UTHSCSA), which is a short distance from the Texas Biomedical Research Institute
(Texas Biomed)/Southwest National Primate Research Center (SNPRC). Core D will closely interact with the
scientific Core C (Primate Core). Core D will also support the imaging studies outlined in Projects 1 and 3 of
this Program Project. Imaging modalities to be utilized in these projects include positron emission tomography
(PET) of copper-64 radiolabeled agents and magnetic resonance imaging (MRI). Specific Aims are: 1) Develop
procedures for radiolabeling monoclonal antibodies, virus and vaccines for lymphatic localization and
pharmacokinetic studies by PET imaging; 2) Develop imaging protocols for monitoring lymphatic drainage
pathways and lymph node localization in rhesus macaques by PET and MRI; 3) Perform PET imaging studies
of radiolabeled monoclonal antibodies administered by the intravenous or mucosal routes and radiolabeled
virus by the mucosal route (Project 1); and 4) Perform PET imaging studies of vaccines in rhesus macaques
administered subcutaneously or intranasally (Project 3). Vaccine components (amphiphilic or soluble peptide
immunogen and amphiphilic or soluble CpG adjuvant) will be radiolabeled with copper-64 for lymph node
targeting studies. There were approximately 44,000 new cases of HIV reported in the U.S. in 2011. Currently,
no vaccine that prevents HIV acquisition is available. Also, most of these HIV cases were transmitted across a
mucosal barrier. Imaging technology developed by this Core will be used by program scientists to understand
the movement of virus and monoclonal antibodies across the mucosal barrier and assist in the characterization
of new HIV vaccines. This project may lead to new radiolabeling techniques and new imaging protocol and
image analysis methodology that can facilitate the development of effective HIV vaccines.

## Key facts

- **NIH application ID:** 10008959
- **Project number:** 5P01AI048240-16
- **Recipient organization:** UNIVERSITY OF LOUISIANA AT LAFAYETTE
- **Principal Investigator:** PETER Thornton FOX
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $230,704
- **Award type:** 5
- **Project period:** 2000-09-30 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10008959

## Citation

> US National Institutes of Health, RePORTER application 10008959, Imaging (5P01AI048240-16). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10008959. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*